The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and its Diagnostic Components in Patients With Mixed Dyslipidemia
- Harold E. Bays, MD (HBaysMD{at}aol.com)1,
- Eli M. Roth, MD2,
- James M. McKenney, PharmD3,
- Maureen T. Kelly, MD4,
- Kamlesh M. Thakker, PhD4,
- Carolyn M. Setze, MS4,
- Katie Obermeyer, MS4 and
- Darryl J. Sleep, MD4
Abstract
Objective: To compare fenofibric acid (FA) + statin to monotherapies on the prevalence of metabolic syndrome (MetSyn) and its diagnostic components in patients with mixed dyslipidemia.
Research Design and Methods: Post-hoc analysis of over 2000 MetSyn patients administered either FA + low- or moderate-dose statin, FA alone, or low-, moderate-, or high-dose statin alone.
Results: FA + low- or moderate-dose statin combination therapy reduced the presence of MetSyn (35.7% or 35.9%, respectively) more than low-, moderate-, or high-dose statin monotherapy (15.5%, 16.6%, or 13.8%, respectively), mostly due to improvements in triglycerides and HDL-C levels. Mean glucose levels slightly decreased with FA monotherapy, slightly increased with statin monotherapy, and were essentially unchanged with FA + statin. FA with or without statin also reduced non–HDL-C, apoB, total cholesterol, very low-density lipoprotein cholesterol, and high sensitivity C-reactive protein.
Conclusions: FA + statin in patients with mixed dyslipidemia reduces the prevalence of MetSyn.
Footnotes
- Received February 23, 2010.
- Accepted June 16, 2010.
- Copyright © American Diabetes Association
